The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes

Clinical Immunology

Volumn 90, Issue 2, 1999, Pages 238-246

  Plaeger, Susan ^a   Bass, Hong Z ^a   Nishanian, Parunag ^a   Thomas, John ^a   Aziz, Najib ^a   Detels, Roger ^a   King, Joy ^a   Cumberland, William ^a   Kemeny, Margaret ^a   Fahey, John L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activation; HIV; Immunology; Immunophenotyping; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; CD71 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032907344     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1998.4646     Document Type: Article

References (50)

1. Fahey, J. L., Taylor, J. M. G., Detels, R., et al. The prognosis value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 322, 166-172, 1990.
2. Fuchs, D., Jager, H., Popescu, M., Reibnegger, G., Werner, E. R., Dierich, M. P., Kaboth, W., Tilz, G. P., and Wachter, H. Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol. Lett. 26, 75-80, 1990.
3. Osmond, D. H., Shiboski, S., Bacchetti, P., Winger, E. E., and Moss, A. R. Immune activation markers and AIDS prognosis. AIDS 5, 505-511, 1991.
4. Melmed, R. N., Taylor, J. M. G., Detels, R., Bozorgmehri, M., and Fahey, J. L. Serum neopterin changes in HIV-1 infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J. Acq. Immun. Def. Synd. 2, 70-76, 1989.
5. Hofmann, B., Wang, Y. X., Cumberland, W. C., Detels, R., Bozorgmehri, M., and Fahey, J. L. Serum β2-microglobulin level increases in HIV-1 infection: Relation to seroconversion, CD4 T cell fall and prognosis. AIDS 4, 207-213, 1989.
6. Hofmann, B., Nishanian, P., Fahey, J. L. et al. Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV-1 infection: Distinctive parameters of HIV-1-induced changes. Clin. Immunol. Immunopathol. 61, 212-224, 1991.
7. Prince, H. E., Kleinman, S., and Williams, A. E. Soluble IL-2 receptor levels in blood donors seropositive for HIV. J. Immunol. 140, 1139-1141, 1988.
8. Honda, M., Kitamura, K., Matsuda, K., et al. Soluble IL-2 receptors in AIDS. Correlation of its serum level with classification of HIV-1 induced diseases and its characterization. J. Immunol. 142, 4248-4255, 1989.
9. Nishanian, P., Hofmann, B., Wang, Y. X., Jackson, A. L., Detels, R., and Fahey, J. L. Serum soluble CD8 molecule is a marker of CD8 T cell activation in HIV1I disease. AIDS 5, 805-812, 1991.
10. Aukrust, P., Liabakk, N. B., Muller, F., Lien, E., Espevik, T., and Frøland, S. S. Serum level of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection: Correlations to clinical, immunologic and virologic parameters. J. Infect. Dis. 169, 420-424, 1994.
11. Jacobson, M., Bacchetti, P., Kolokathis, A., et al. Surrogate markers for survival in patients with AIDS and AIDS-related complex treated with zidovudine. Br. Med. J. 320, 73-78, 1990.
12. Bass, H. Z., Hardy, W. D., Mitsuyasu, R. T., et al. The effect of zidovudine treatment on serum neopterin and β2-microglobulin levels in mildly symptomatic, human immunodeficiency virus type-1 (HIV-1-1) seropositive individuals. J. Acq. Immun. Def. Synd. 5, 215-221, 1992.
13. Bass, H. Z., Nishanian, P., Hardy, W. D., Mitsuyasu, R. T., Esmail, E., Cumberland, W., and Fahey, J. L. Immune changes in HIV-infection: Significant correlations and differences in serum markers and lymphoid phenotypic antigens. Clin. Immunol. Immunopathol. 64, 63-70, 1992.
14. Prince, H. E., Kleinman, S., Czaplicki, J. C., and Williams, A. E. Interrelationship between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J. AIDS 3, 525-530, 1990.
15. Yagi, M. J., Chu, F. N., Jiang, J. D., et al. Increase in soluble CD8 antigen in plasma and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection. Clin. Immunol. Immunopathol. 63, 126-134, 1992.
16. Giorgi, J. V., Liu, Z., Hultin, L. E., et al. Elevated levels of CD38 + CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J. AIDS 6, 904-912, 1993.
17. Zola, H., Koh, L. Y., Mantzioris, B. X., and Rhodes, D. Patients with HIV infection have a reduced proportion of lymphocytes expressing the IL-2 receptor p55 chain (TAC, CD25). Clin. Immunol. Immunopathol. 59, 16-25, 1991.
18. Bass, H. Z., Fahey, J. L., Nishanian, P., Detels, R., Cumberland, W., Kemeny, M., and Plaeger, S. Relation of impaired lymphocyte proliferative function to other major human immunodeficiency virus type 1-induced immunological changes. Clin. Diag. Lab. Immunol. 4, 64-69, 1997.
19. Lane, H. C., and Fauci, A. S. Immunologic abnormalities in the acquired immunodeficiency syndrome. Ann. Rev. Immunol. 3, 477-500, 1985.
20. El-Sadr, W., Mormor, M., Zolla-Pazner, S., et al. Four-year prospective study of homosexual men: Correlation of immunologic abnormalities, clinical status, and serology to human immunodeficiency virus. J. Infect. Dis. 155, 789-795, 1987.
21. Giorgi, J. V., Nishanian, P. G., Schmid, I., Hultin, L. E., Cheng, H. L., and Detels, R. Selective alterations in immunoregulatory lymphocyte subsets in early HIV-1 (human T lymphotropic virus type III/lymphadenopathy-associated virus) infection. J. Clin. Immunol. 7, 140-150, 1987.
22. Polk, B. F., Fox, R., Brookmeyer, R., et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N. Engl. J. Med. 316, 61-66, 1988.
23. Giorgi, J. V., and Detels, R. T-cell subset alterations in HIV-1-infected homosexual men: NIAID multicenter AIDS cohort study. Clin. Immunol. Immunopathol. 52, 10-18, 1989.
24. Moss, A. R., Bacchetti, P., Osmond, D., et al. Seropositively for HIV-1 and the development of AIDS or AIDS related condition: Three-year follow-up on the San Francisco General Hospital Cohort. Br. Med. J. 296, 745-750, 1988.
25. Taylor, J. M. G., Fahey, J. L., Detels, R., et al. CD4 percentage, CD4 number and CD4:CD8 ratio in HIV infection: Which to choose and how to use. J. AIDS 2, 114-124, 1989.
26. Stein, D. S., Korviex, J. A., and Vermund, S. H. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J. Infect. Dis. 165, 352-356, 1992.
27. Tsoukas, C. M., and Bernard, N. F. Markers predicting progression of human immunodeficiency virus related disease. Clin. Microbiol. Rev. 7, 14-28, 1994.
28. Hofmann, B., Bygbjerg, I., Dickmeiss, E., et al. Prognostic value of immunologic abnormalities and HIV antigenemia in asymptomatic HIV-infected individuals: Proposal of Immunologic staging. Scand. J. Infect. Dis. 21, 633-643, 1989.
29. Kramer, A., Biggar, R. J., Hampg, H., Friedman, R. M., Fuchs, D., Wachter, H., and Goedert, J. J. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific. Am. J. Epidemiol 136, 71-80, 1990.
30. Choi, Sungsub, Lagakos, S. W., Schooley, R. T., and Volberding, P. A. CD4+ Lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Am. Coll. Phys. 674, 1993.
31. Graham, N. M., Piantadosi, S., Park, L. P., Phair, J. P., Rinaldo, C. R., and Fahey, J. L. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. J. AIDS 6, 1258-1266, 1993.
32. Kaslow, R. A., Ostow, D. G., Detels, R., Phair, J. P., Polk, B. F., and Rinaldo, C. R. The multicenter AIDS cohort study: Rationale, organization and selected characteristics of the participants. Am. J. Epidemiol. 126, 310-318, 1987.
33. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbid. Mortal. Weekly Rep. 36, 3S-15S, 1987.
34. Schellekens, P. T., Roos, M. T., De Wolf, F., Lange, J. M., and Miedema, F. Low T-cell responsiveness to activation via CD3/ TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J. Clin. Immunol. 10, 121-127, 1990.
35. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. Series B: 187-220, 1972.
36. Mellors, J. W., Rinaldo, C. R., Gupta, P., et al. Prognosis in HIV infection predicted by the quantity of virus in plasma. Science 272, 1167-1171, 1996.
37. Mellors, J. W., Munoz, A., Giorgi, J. V., et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126, 946-954, 1997.
38. Verhofstede, C., Reniers, S., Van Wanzeele, F., and Plum, J. Evaluation of proviral copy number and plasma RNA levels as early indicators of progression in HIV-1 infection: Correlation with virologic and immunological markers of disease. AIDS 8, 1421-1427, 1994.
39. Prince, H. E., Kermani-Arab, V., and Fahey, J. L. Depressed interleukin-2 receptor expression in acquired immune deficiency and lymphoadenopathy syndromes. J. Immunol. 133, 1313-1317, 1984.
40. Martinez-Maza, O., Crabb, E., Mitsuyasu, R. T., Fahey, J. L., and Giorgi, J. V. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J. Immunol. 138, 3720-3724, 1987.
41. Amadori, A., and Chieco-Bianchi, L. B-cell activation in HIV infection: deeds and misdeeds. Immunol. Today 11, 374-379, 1990.
42. Fuchs, D., Hansen, A., Reibnegger, G., et al. Interferon-gamma concentrations are increased in sera from individuals infected with human immunodeficiency virus type-1. J. AIDS 2, 158-162, 1989.
43. Fan, J., Bass, H. Z., and Fahey, J. L. Elevated IFN-γ and decreased IL-2 gene expression are associated with HIV infection. J. Immunol. 151, 5031-5040, 1993.
44. Dezube, B. J., Pardee, A. B., Beckett, L. A., et al. Cytokine dysregulation in AIDS: In vivo overexpression of mRNA of tumor necrosis factor-α and its correlation with that of the inflammatory cytokine GRO. J. AIDS 5, 1099-1104, 1992.
45. Breen, E. C., Rezai, A. R., Nakajima, K., Beall, G. N., Mitsuyasu, R. T., Hirano, T., Kishimoto, T., Martinez-Maza, O. Infection with HIV is associated with elevated IL-6 levels and production. J. Immunol. 144, 480-485, 1990.
46. Poli, G., Kinter, A., Justement, J. S., et al. Tumor necrosis factor-α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc. Natl. Acad. Sci. USA 87, 782-785, 1990.
47. Huber, C., Batchelor, J. R., Fuchs, D., et al. Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon-gamma. J. Exp. Med. 160, 310-316, 1984.
48. Fahey, J. L. Cytokines, plasma immune activation markers and clinically relevant markers in HIV infection. Clin. Diag. Lab. Immunol. 5, 597-603, 1998.
49. Fahey, J. L., Taylor, J. M. G., Manna, B., Nishanian, P., Aziz, N., Giorgi, J. V., and Detels, R. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T cell measurements. AIDS 12, 1581-1590, 1998.
50. Salazar-Gonzalez, J. F., Martinez-Maza, O., Aziz, N., Kolberg, J., Yeghiazarian, T., Shen, L.-P., and Fahey, J. L. Relationship of plasma HIV-RNA levels and levels of TNF-α and immune activation products in HIV infection. Clin. Immunol. Immunopathol. 84, 36-45, 1997.